Find the product you need

News

Paclitaxel [33069-62-4]

Catalog number: AG-CN2-0045-M001
Brand: AdipoGen Life Sciences
Packing: 1 mg
Other sizes: Other sizes available
Price: € 25.00
Expected delivery time: 7 days
Quantity:
Spin UpSpin Down
Chemical Structure
Chemical Structure...

Product specifications for - Paclitaxel [33069-62-4]

Overview: 
Product group: Chemicals
Category: Other
CAS No.: 33069-62-4
Properties: 
Purity: >99%
Molecular Formula: C47H51NO14
Molecular weight: 853.9
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Storage instructions: 2-¦C to 8-¦C, -20-¦C
Scientific information: 
Scientific info: Anticancer compound. Chemotherapeutic used in patients with cancer and advanced forms of Kaposis sarcoma. Microtubule assembly stabilizer. Reversibly binds to polymerized tubulin. Anti-mitotic. Mitotic spindle assembly, chromosome segregation and cell division inhibitor. Induces cell cycle arrest at the G2/M phase. Apoptosis inducer through aberrant activation of cyclin-dependent kinases (CKDs) and the c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK). Immunosuppressor. Immunostimulant. Antiproliferative agent for the prevention of restenosis. TRAIL sensitizer - Chemical. CAS: 33069-62-4. Formula: C47H51NO14. MW: 853.9. Isolated from the bark of the pacific yew tree (Taxus brevifolia). Anticancer compound. Chemotherapeutic used in patients with cancer and advanced forms of Kaposis sarcoma. Microtubule assembly stabilizer. Reversibly binds to polymerized tubulin. Anti-mitotic. Mitotic spindle assembly, chromosome segregation and cell division inhibitor. Induces cell cycle arrest at the G2/M phase. Apoptosis inducer through aberrant activation of cyclin-dependent kinases (CKDs) and the c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK). Immunosuppressor. Immunostimulant. Antiproliferative agent for the prevention of restenosis. TRAIL sensitizer
Safety information: 
MSDS: MSDS
Hazard information: Danger, Non-hazardous
Additional information: 
Synonyms: AG-CN2-0045-M001
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines: J.E. Liebmann, et al.; Br. J. Cancer 68, 1104 (1993) Read more
Taxol (paclitaxel): mechanisms of action: S.B. Horwitz; Ann. Oncol. 5, S3 (1994) (Review) Read more
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity: R. Foa, et al.; Int. J. Clin. Lab. Res. 24, 6 (1994) (Review) Read more
Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway: C.M. Woods, et al.; Mol. Med. 1, 506 (1995) Read more
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle: A. Jordan, et al.; Med. Res. Rev. 18, 259 (1998) Read more
How Taxol stabilises microtubule structure: L.A. Amos & J. Löwe; Chem. Biol. 6, R65 (1999) (Review) Read more
Mechanisms of Taxol-induced cell death are concentration dependent: K. Torres & S.B. Horwitz; Cancer Res. 58, 3620 (1998) Read more
Molecular effects of paclitaxel: myths and reality (a critical review): M.V. Blagosklonny & T. Fojo; Int. J. Cancer 83, 151 (1999) Read more
Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK) dependent and -independent pathways in ovarian cancer cells: T.H. Wang, et al.; J. Biol. Chem. 274, 8208 (1999) Read more
Paclitaxel-induced cell death: where the cell cycle and apoptosis come together: T.H. Wang, et al.; Cancer 88, 2619 (2000) Read more
See All